Is Abeona Therapeutics Inc. (ABEO) a Buy, Sell, or Hold?
NASDAQ : ABEO
Abeona Therapeutics Inc.
$7.02 USD
-$0.27 (-3.7%)
- Volume
- 1.1M
- Average Volume
- 1.19M
- Market Capitalization
- $400.11M
- P/E Ratio
- 5.46
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $7.54
- Year Low
- $4.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.89
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Vishwas Seshadri |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ABEO |
| CUSIP | 00289Y206 |
| CIK | 0000318306 |
| Web | https://www.abeonatherapeutics.com |
| Phone | 646 813 4701 |
| Currency | USD |
| Employees | 226 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.16 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.89 |
| Quick Ratio | 5.70 |
| Cash Ratio | 1.98 |
Sales & Book Value
| Annual Sales | $5.82M |
| Price / Sales | 27.52 |
| Cash Flow | -1.51 |
| Price / Cash Flow | -4.69 |
| Price / Book | 2.74 |
Price Target and Rating
| Average Stock Price Forecast | $17.00 |
| High Stock Price Forecast | $17.00 |
| Low Stock Price Forecast | $17.00 |
| Forecast Upside/Downside | -58.71% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.01 |
| Trailing P/E Ratio | 5.46 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $71.18M |
| Net Margin | 454.86% |
| Pretax Margin | 455.56% |
| Return on Equity | 41.40% |
| Return on Assets | 33.32% |
Financials Score
| AltmanZ Score | 1.31 |
| Piotroski Score | 6.00 |
| Working Capital | 151.94M |
| Total Assets | 198.49M |
| Ebit | 69.81M |
| Market Cap | 402.39M |
| Total Liabilities | 53.56M |
Poll Results
About Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was foun ... ded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 07:30:00
CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 08:30:00
CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
2026-05-26 08:30:00
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026:
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
2026-05-13 15:50:47
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Abeona Therapeutics Q1 Earnings Call Highlights
2026-05-13 10:08:38
Abeona Therapeutics NASDAQ: ABEO reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company's earnings call.
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
2026-05-13 09:31:36
Abeona Therapeutics Inc. (NASDAQ:ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
2026-05-13 07:30:00
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN. Steady increase in ZEVASKYN adoption with three patients completing treatment in the first quarter of 2026, one treatment to date in the second quarter, one biopsy currently in manufacturing process, and six additional patients expected to be biopsied in the second quarter, three of whom have biopsies scheduled.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-11 14:30:00
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Thera
Frequently Asked Questions
-
What is the current Abeona Therapeutics Inc. (ABEO) stock price?
-
Abeona Therapeutics Inc.(NASDAQ:ABEO) stock price is $7.02 in the last trading session. During the trading session, ABEO stock reached the peak price of $7.54 while $4 was the lowest point it dropped to. The percentage change in ABEO stock occurred in the recent session was --3.7% while the dollar amount for the price change in ABEO stock was -$0.27.
-
ABEO's industry and sector of operation?
-
The NASDAQ listed ABEO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ABEO?
-
Jon Voss | Vice President & Head of Quality
Brendan O'Malley | Chief Legal Officer
Madhav Vasanthavada | Senior Vice President, Chief Commercial Officer & Head of Business Development
James A. Gow | SVP, Head of Clinical Development & Medical Affairs
Brian Kevany | Chief Technical & Scientific Officer -
How many employees does ABEO have?
-
Number of ABEO employees currently stands at 226. ABEO operates from 1330 Avenue of the Americas, Cleveland, OH 10019, US.
-
Link for ABEO official website?
-
Official Website of ABEO is: https://www.abeonatherapeutics.com
-
How do I contact ABEO?
-
ABEO could be contacted at phone #646 813 4701 and can also be accessed through its website. ABEO operates from 1330 Avenue of the Americas, Cleveland, OH 10019, US.
-
How many shares of ABEO are traded daily?
-
The average number of ABEO shares traded daily for last 3 months was 1.19M.
-
What is the market cap of ABEO currently?
-
The market value of ABEO currently stands at $400.11M with its latest stock price at $7.02